Physician profile
Bableen Kaur
NPI 1215798913
$685.95
in general payments reported to CMS, 2019-2025
15 companies · $667 in 2025
The $667 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $18.94 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $274.73 | 2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $91.92 | 2025 | Airsupra, Farxiga |
| Grifols USA, LLC | $56.28 | 2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $49.02 | 2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $32.04 | 2025 | |
| Pfizer INC. | $25.86 | 2025 | |
| Boston Scientific Corporation | $21.57 | 2025 | Wavewriter Alpha Prime 16 |
| Sumitomo Pharma America, INC. | $20.09 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.94 | 2024 | Caplyta |
| Exact Sciences Corporation | $18.51 | 2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $17.61 | 2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $16.34 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.95 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.49 | 2025 | Jardiance |
| Amgen INC. | $13.60 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bableen Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.